The orally available cathepsin S inhibitor RO546111 was shown to reduce the activation of splenic DCs and the subsequent activation of CD4+ T cells, to diminish hypergammaglobulinemia and anti-dsDNA antibody levels and prevent lupus nephritis progression in MRL/lpr lupus mice (113). This evidence concerns the gene CTSS and lupus nephritis.